Guidelines For The Prevention And Treatment Of Glucocorticoid-induced Osteoporosis

dc.creatorPereira R.M.R.
dc.creatorde Carvalho J.F.
dc.creatorPaula A.P.
dc.creatorZerbini C.
dc.creatorDomiciano D.S.
dc.creatorGoncalves H.
dc.creatorDanowski J.S.
dc.creatorMarques Neto J.F.
dc.creatorMendonca L.M.C.
dc.creatorBezerra M.C.
dc.creatorTerreri M.T.
dc.creatorImamura M.
dc.creatorWeingrill P.
dc.creatorPlapler P.G.
dc.creatorRadominski S.
dc.creatorTourinho T.
dc.creatorSzejnfeld V.L.
dc.creatorAndrada N.C.
dc.date2012
dc.date2015-06-26T20:29:49Z
dc.date2015-11-26T14:26:27Z
dc.date2015-06-26T20:29:49Z
dc.date2015-11-26T14:26:27Z
dc.date.accessioned2018-03-28T21:29:30Z
dc.date.available2018-03-28T21:29:30Z
dc.identifier
dc.identifierRevista Brasileira De Reumatologia. , v. 52, n. 4, p. 580 - 593, 2012.
dc.identifier4825004
dc.identifier10.1590/S0482-50042012000400009
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84866492201&partnerID=40&md5=129b0503f8bd8a70d4888cbe55fe57dd
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/97180
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/97180
dc.identifier2-s2.0-84866492201
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1246086
dc.descriptionGlucocorticoids (GC) are used in almost all medical specialties, and approximately 0.5% of the general population of the United Kingdom receives those medications. With the increased survival of patients with rheumatological diseases, morbidity secondary to the use of those medications represents an important aspect of the management of our patients. The incidences of vertebral and non-vertebral fractures are elevated, ranging from 30% to 50% of the individuals on GC for over three months. Thus, osteoporosis and frailty fractures should be prevented and treated in all patients initiating or already on GC. There are several recommendations on this topic elaborated by several international societies, but consensus still lacks. Recently, the American College of Rheumatology has published new recommendations, but they are based on the WHO Fracture Risk Assessment Tool (FRAX®) to evaluate the risk for each individual, and, thus, cannot be completely used for the Brazilian population. Thus, the Committee for Osteoporosis and Bone Metabolic Disorders of the Brazilian Society of Rheumatology, along with the Brazilian Medical Association and the Brazilian Association of Physical Medicine and Rehabilitation, has elaborated the Brazilian Guidelines for Glucocorticoid-Induced Osteoporosis (GIO), based on the better available scientifi c evidence and/or expert experience. Method of evidence collection: The bibliographic review of scientifi c articles of this guideline was performed in the MEDLINE database. The search for evidence was based on real clinical scenarios, and used the following keywords (MeSH terms): Osteoporosis, Osteoporosis/chemically induced*= (Glucocorticoids= Adrenal Cortex Hormones, Steroids), Glucocorticoids, Glucocorticoids/administration and dosage, Glucocorticoids/therapeutic use, Glucocorticoids/adverse effects, Prednisone/adverse effects, Dose-Response Relationship, Drug, Bone Density/drug effects, Bone Density Conservation Agents/pharmacological action, Osteoporosis/prevention & control, Calcium, Vitamin D, Vitamin D defi ciency, Calcitriol, Receptors, Calcitriol; 1-hydroxycholecalciferol, Hydroxycholecalciferols, 25-Hydroxyvitamin D3 1-alpha-hydroxylase OR Steroid Hydroxylases, Prevention and Control, Spinal fractures/prevention & control, Fractures, Spontaneous, Lumbar Vertebrae/injuries, Lifestyle, Alcohol Drinking, Smoking OR tobacco use disorder, Movement, Resistance Training, Exercise Therapy, Bone density OR Bone and Bones, Dual-Energy X-Ray Absorptiometry OR Absorptiometry Photon OR DXA, Densitometry, Radiography, (Diphosphonates Alendronate OR Risedronate Pamidronate OR propanolamines OR Ibandronate OR Zoledronic acid, Teriparatide OR PTH 1-34, Men AND premenopause, pregnancy, pregnancy outcome maternal, fetus, lactation, breast-feeding, teratogens, Children (6-12 years), adolescence (13-18 years). Grade of recommendation and level of evidence: A) Data derived from more consistent experimental and observational studies; B) Data derived from less consistent experimental and observational studies; C) Case reports (uncontrolled studies); D) Expert opinion without explicit critical appraisal, or based on consensus, physiological studies or animal models. Objective: To establish guidelines for the prevention and treatment of GIO. © 2012 Elsevier Editora Ltda.
dc.description52
dc.description4
dc.description580
dc.description593
dc.descriptionWalsh, L.J., Wong, C.A., Pringle, M., Tattersfield, A.E., Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study (1996) BMJ, 313 (7053), pp. 344-346
dc.descriptionvan Staa, T.P., Leufkens, H.G., Cooper, C., The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis (2002) Osteoporos Int, 13 (10), pp. 777-787
dc.descriptionKaji, H., Yamauchi, M., Chihara, K., Sugimoto, T., The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis (2006) Endocr J, 53 (1), pp. 27-34
dc.descriptionVan Staa, T.P., Laan, R.F., Barton, I.P., Cohen, S., Reid, D.M., Cooper, C., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy (2003) Arthritis Rheum, 48 (11), pp. 3224-3229
dc.descriptionVan Staa, T.P., Leufkens, H.G., Abenhaim, L., Zhang, B., Cooper, C., Use of oral corticosteroids and risk of fracture. June, 2000 (2005) J Bone Miner Res, 20 (8), pp. 1487-1494
dc.descriptionAmerican College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Arthritis Rheum, 44 (7), pp. 1496-1503. , Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
dc.descriptionAdler, R.A., Hochberg, M.C., Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs (2003) Arch Intern Med, 163 (21), pp. 2619-2624
dc.descriptionGeusens, P.P., de Nijs, R.N., Lems, W.F., Laan, R.F., Struijs, A., van Staa, T.P., Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology (2004) Ann Rheum Dis, 63 (3), pp. 324-325
dc.description(2002) Glucocorticoidinduced Osteoporosis: guidelines for prevention and treatment, , National Osteoporosis Society & Royal College of Physicians guidelines working group for Bone and Tooth Society, London, Royal College of Physicians
dc.descriptionDevogelaer, J.P., Goemaere, S., Boonen, S., Body, J.J., Kaufman, J.M., Reginster, J.Y., Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club (2006) Osteoporos Int, 17 (1), pp. 8-19
dc.descriptionNawata, H., Soen, S., Takayanagi, R., Tanaka, I., Takaoka, K., Fukunaga, M., Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004) (2005) J Bone Miner Metab, 23 (2), pp. 105-109
dc.descriptionGrossman, J.M., Gordon, R., Ranganath, V.K., Deal, C., Caplan, L., Chen, W., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis (2010) Arthritis Care Res (Hoboken), 62 (11), pp. 1515-1526
dc.descriptionSambrook, P., Birmingham, J., Kelly, P., Kempler, S., Pocock, N., Eisman, J., Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin (1993) N Engl J Med, 328 (24), pp. 1747-1752
dc.descriptionYeap, S.S., Fauzi, A.R., Kong, N.C., Halim, A.G., Soehardy, Z., Rahimah, I., A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus (2008) J Rheumatol, 35 (12), pp. 2344-2347
dc.descriptionPoulos, P., Adachi, J.D., Guidelines for the prevention and therapy of glucocorticoid-induced osteoporosis (2000) Clin Exp Rheumatol, 18 (SUPPL. 21), pp. S79-S86
dc.descriptionRichy, F., Ethgen, O., Bruyere, O., Reginster, J.Y., Effi cacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate (2004) Osteoporos Int, 15 (4), pp. 301-310
dc.descriptionSambrook, P., Henderson, N.K., Keogh, A., MacDonald, P., Glanville, A., Spratt, P., Effect of calcitriol on bone loss after cardiac or lung transplantation (2000) J Bone Miner Res, 15 (9), pp. 1818-1824
dc.descriptionde Nijs, R.N., Jacobs, J.W., Algra, A., Lems, W.F., Bijlsma, J.W., Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies (2004) Osteoporos Int, 15 (8), pp. 589-602
dc.descriptionRinge, J.D., Dorst, A., Faber, H., Schacht, E., Rahlfs, V.W., Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoidinduced osteoporosis (2004) Rheumatol Int, 24 (2), pp. 63-70
dc.descriptionHomik, J., Suarez-Almazor, M.E., Shea, B., Cranney, A., Wells, G., Tugwell, P., Calcium and vitamin D for corticosteroid-induced osteoporosis (2000) Cochrane Database Syst Rev, (2), pp. CD000952
dc.descriptionBuckley, L.M., Leib, E.S., Cartularo, K.S., Vacek, P.M., Cooper, S.M., Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis (1996) Ann Intern Med, 125 (12), pp. 961-968
dc.descriptionJensen, J., Christiansen, C., Rødbro, P., Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause (1985) N Engl J Med, 313 (16), pp. 973-975
dc.descriptionKorkor, A.B., Eastwood, D., Bretzmann, C., Effects of gender, alcohol, smoking, and dairy consumption on bone mass in Wisconsin adolescents (2009) WMJ, 108 (4), pp. 181-188
dc.descriptionTeucher, B., Dainty, J.R., Spinks, C.A., Majsak-Newman, G., Berry, D.J., Hoogewerff, J.A., Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women (2008) J Bone Miner Res, 23 (9), pp. 1477-1485
dc.descriptionPongchaiyakul, C., Nguyen, T.V., Kosulwat, V., Rojroongwasinkul, N., Charoenkiatkul, S., Eisman, J.A., Effects of physical activity and dietary calcium intake on bone mineral density and osteoporosis risk in a rural Thai population (2004) Osteoporos Int, 15 (10), pp. 807-813
dc.descriptionEnsrud, K.E., Ewing, S.K., Taylor, B.C., Fink, H.A., Stone, K.L., Cauley, J.A., Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures (2007) J Gerontol A Biol Sci Med Sci, 62 (7), pp. 744-751
dc.descriptionMorin, S., Tsang, J.F., Leslie, W.D., Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years (2009) Osteoporos Int, 20 (3), pp. 363-370
dc.descriptionHodgson, S.F., Watts, N.B., Bilezikian, J.P., Clarke, B.L., Gray, T.K., Harris, D.W., American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 (2003) Endocr Pract, 9 (6), pp. 544-564
dc.descriptionKohrt, W.M., Bloomfield, S.A., Little, K.D., Nelson, M.E., Yingling, V.R., American College of Sports Medicine. American College of Sports Medicine Position Stand: physical activity and bone health (2004) Med Sci Sports Exerc, 36 (11), pp. 1985-1996
dc.descriptionSchmitt, N.M., Schmitt, J., Dören, M., The role of physical activity in the prevention of osteoporosis in postmenopausal women (2009) An update. Maturitas, 63 (1), pp. 34-38
dc.descriptionGillespie, L.D., Robertson, M.C., Gillespie, W.J., Lamb, S.E., Gates, S., Cumming, R.G., Interventions for preventing falls in older people living in the community (2009) Cochrane Database Syst Rev, 15 (2), pp. CD007146
dc.descriptionMaricic, M., Glucocorticoid-induced osteoporosis: treatment options and guidelines (2005) Curr Osteoporos Rep, 3 (1), pp. 25-29
dc.descriptionBraith, R.W., Magyari, P.M., Fulton, M.N., Aranda, J., Walker, T., Hill, J.A., Resistance exercise training and alendronate reverse glucocorticoidinduced osteoporosis in heart transplant recipients (2003) J Heart Lung Transplant, 22 (10), pp. 1082-1090
dc.descriptionNewman, E.D., Matzko, C.K., Olenginski, T.P., Perruquet, J.L., Harrington, T.M., Maloney-Saxon, G., Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year (2006) Osteoporos Int, 17 (9), pp. 1428-1434
dc.descriptionde Jong, Z., Munneke, M., Lems, W.F., Zwinderman, A.H., Kroon, H.M., Pauwels, E.K., Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial (2004) Arthritis Rheum, 50 (4), pp. 1066-1076
dc.descriptionAngeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study (2006) Bone, 39 (2), pp. 253-259
dc.descriptionLewiecki, E.M., Gordon, C.M., Baim, S., Leonard, M.B., Bishop, N.J., Bianchi, M.L., International Society for Clinical Densitometry 2007 Adult and Pediatric Offi cial Positions (2008) Bone, 43 (6), pp. 1115-1121
dc.descriptionReid, D.M., Adami, S., Devogelaer, J.P., Chines, A.A., Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy (2001) Calcif Tissue Int, 69 (4), pp. 242-247
dc.descriptionCruse, L.M., Valeriano, J., Vasey, F.B., Carter, J.D., Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men (2006) J Clin Rheumatol, 12 (5), pp. 221-225
dc.descriptionVan Staa, Leufkens, H.G., Abenhaim, L., Zhang, B., Cooper, C., Use of Oral Corticosteroids and Risk of Fracture J Bone Min Res, 15 (6), p. 2000
dc.descriptionvan Staa, T.P., Cooper, C., Leufkens, H.G., Bishop, N., Children and the risk of fractures caused by oral corticosteroids (2003) J Bone Miner Res, 18 (5), pp. 913-918
dc.descriptionBlodgett, F.M., Burgin, L., Iezzoni, D., Gribetz, D., Talbot, N.B., Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children (1956) N Engl J Med, 254 (14), pp. 636-641
dc.descriptionVaronos, S., Ansell, B.M., Reeve, J., Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy (1987) Calcif Tissue Int, 41 (2), pp. 75-78
dc.descriptionBaim, S., Binkley, N., Bilezikian, J.P., Kendler, D.L., Hans, D.B., Lewiecki, E.M., Offi cial Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference (2008) J Clin Densitom, 11 (1), pp. 75-91
dc.descriptionSaag, K.G., Emkey, R., Schnitzer, T.J., Brown, J.P., Hawkins, F., Goemaere, S., Alendronate for the prevention and treatment of glucocorticoidinduced osteoporosis (1998) N Engl J Med, 339 (5), pp. 292-299
dc.descriptionCohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M., Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (1999) Arthritis Rheum, 42 (11), pp. 2309-2318
dc.descriptionde Nijs, R.N., Jacobs, J.W., Lems, W.F., Laan, R.F., Algra, A., Huisman, A.M., Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis (2006) N Engl J Med, 355 (7), pp. 675-684
dc.descriptionWallach, S., Cohen, S., Reid, D.M., Hughes, R.A., Hosking, D.J., Laan, R.F., Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy (2000) Calcif Tissue Int, 67 (4), pp. 277-285
dc.descriptionAdachi, J.D., Saag, K.G., Delmas, P.D., Liberman, U.A., Emkey, R.D., Seeman, E., Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial (2001) Arthritis Rheum, 44 (1), pp. 202-211
dc.descriptionCohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M., Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (1999) Arthritis Rheum, 42 (11), pp. 2309-2318
dc.descriptionBlack, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis (2007) N Engl J Med, 356 (18), pp. 1809-1822
dc.descriptionLyles, K.W., Colón-Emeric, C.S., Magaziner, J.S., Adachi, J.D., Pieper, C.F., Mautalen, C., Zoledronic acid in reducing clinical fracture and mortality after hip fracture (2007) N Engl J Med, 357, pp. 1799-1809
dc.descriptionReid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y., Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial (2009) Lancet, 373 (9671), pp. 1253-1263
dc.descriptionRietbrock, S., Olson, M., van Staa, T.P., The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates (2009) QJM, 102 (1), pp. 35-42
dc.descriptionLau, A.N., Adachi, J.D., Role of teriparatide in treatment of glucocorticoid-induced osteoporis (2010) Ther Clin Risk Manag, 6, pp. 497-503
dc.descriptionCanalis, E., Giustina, A., Bilezikian, I.P., Mechanisms of anabolic therapies for osteoporosis (2007) N Engl J Med, 357 (9), pp. 905-916
dc.descriptionSaag, K.G., Shane, E., Boonen, S., Marín, F., Donley, D.W., Taylor, K.A., Teriparatide or alendronate in glucocorticoid-induced osteoporosis (2007) N Engl J Med, 357 (20), pp. 2028-2039
dc.descriptionSaag, K.G., Zanchetta, J.R., Devogelaer, J.P., Adler, R.A., Eastell, R., See, K., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial (2009) Arthritis Rheum, 60 (11), pp. 3346-3355
dc.descriptionLangdahl, B.L., Marin, F., Shane, E., Dobnig, H., Zanchetta, J.R., Maricic, M., Teriparatide versus alendronate for treating glucorticoid-induced osteoporosis: an analysis by gender and menopausal status (2009) Osteoporosis Int, 20 (12), pp. 2095-2104
dc.descriptionMaricic, M., Gluck, O., Densitometry in glucocorticoid-induced osteoporosis (2004) J Clin Densitometry, 7 (4), pp. 359-363
dc.descriptionFranchimont, N., Canalis, E., Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease (2003) Autoimmun Rev, 2 (4), pp. 224-228
dc.descriptionWinzenberg, T., Oldenburg, B., Frendin, S., De Wit, L., Riley, M., Jones, G., The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260] (2006) BMC Public Health, pp. 6-12
dc.descriptionOkada, Y., Nawata, M., Nakayamada, S., Saito, K., Tanaka, Y., Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy (2008) J Rheumatol, 35 (11), pp. 2249-2254
dc.descriptionAdachi, J.D., Bensen, W.G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Intermittent etidronate therapy to prevent corticosteroidinduced osteoporosis (1997) N Engl J Med, 337 (6), pp. 382-387
dc.descriptionPatlas, N., Golomb, G., Yaffe, P., Pinto, T., Breuer, E., Ornoy, A., Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats (1999) Teratology, 60 (2), pp. 68-73
dc.descriptionMinsker, D.H., Manson, J.M., Peter, C.P., Effects of the bisphosphonate, alendronate, on parturition in the rat (1993) Toxicol Appl Pharmacol, 121 (2), pp. 217-223
dc.descriptionChan, B., Zacharin, M., Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases (2006) J Clin Endocrinol Metab, 91 (6), pp. 2017-2020
dc.descriptionOrnoy, A., Wajnberg, R., Diav-Citrin, O., The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment (2006) Reprod Toxicol, 22 (4), pp. 578-579
dc.descriptionDunlop, D.J., Soukop, M., McEwan, H.P., Antenatal administration of aminopropylidene diphosphonate (1990) Ann Rheum Dis, 49 (11), p. 955
dc.descriptionIllidge, T.M., Hussey, M., Godden, C.W., Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate (1996) Clin Oncol (R Coll Radiol), 8 (4), pp. 257-258
dc.descriptionMunns, C.F., Rauch, F., Ward, L., Glorieux, F.H., Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases (2004) J Bone Miner Res, 19 (10), pp. 1742-1745
dc.descriptionDjokanovic, N., Klieger-Grossmann, C., Koren, G., Does treatment with bisphosphonates endanger the human pregnancy? (2008) J Obstet Gynaecol Can, 30 (12), pp. 1146-1148
dc.descriptionLevy, S., Fayez, I., Taguchi, N., Han, J.Y., Aiello, J., Matsui, D., Pregnancy outcome following in utero exposure to bisphosphonates (2009) Bone, 44 (3), pp. 428-430
dc.descriptionYarrington, J.T., Capen, C.C., Black, H.E., Re, R., Potts Jr, J.T., Geho, W.B., Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion (1976) Am J Pathol, 83 (3), pp. 569-588
dc.descriptionBianchi, M.L., How to manage osteoporosis in children (2005) Best Pract Res Clin Rheumatol, 19 (6), pp. 991-1005
dc.descriptionBrown, J.J., Zacharin, M.R., Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents (2005) J Paediatr Child Health, 41 (11), pp. 580-582
dc.descriptionRoth, J., Bechtold, S., Borte, G., Dressler, F., Girschick, H., Borte, M., Diagnosis, prophylaxis and therapy of osteoporosis in juvenile idiopathic arthritis: consensus statement of the German Association for Pediatric Rheumatology (2007) Z Rheumatol, 66 (5), pp. 434-440
dc.descriptionBianchi, M.L., Cimaz, R., Bardare, M., Zulian, F., Lepore, L., Boncompagni, A., Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study (2000) Arthritis Rheum, 43 (9), pp. 1960-1966
dc.descriptionRudge, S., Hailwood, S., Horne, A., Lucas, J., Wu, F., Cundy, T., Effects of once-weekly oral alendronate on bone in children on glucocorticoids treatment (2005) Rheumatology (Oxford), 44 (6), pp. 813-818
dc.descriptionNoguera, A., Ros, J.B., Pavia, C., Alcover, E., Valls, C., Villaronga, M., Bisphosphonates, a new treatment for glucocorticoids-induced osteoporosis in children (2003) J Pediatr Endocrinol Metab, 16 (4), pp. 529-536
dc.descriptionThornton, J., Ashcroft, D.M., Mughal, M.Z., Elliott, R.A., O'Neill, T.W., Symmons, D., Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis (2006) Arch Dis Child, 91 (9), pp. 753-761
dc.descriptionBatch, J.A., Couper, J.J., Rodda, C., Cowell, C.T., Zacharin, M., Use of bisphosphonte therapy for osteoporosis in childhood and adolescence (2003) J Paediatr Child Health, 39 (2), pp. 88-92
dc.languageen
dc.publisher
dc.relationRevista Brasileira de Reumatologia
dc.rightsfechado
dc.sourceScopus
dc.titleGuidelines For The Prevention And Treatment Of Glucocorticoid-induced Osteoporosis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución